MET exon 14 skipping in advanced NSCLC (~3-4% of adenocarcinoma): capmatinib (GEOMETRY mo...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-MET-EX14-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-MET |
|---|---|
| Variant | exon 14 skipping |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | capmatinib monotherapy, tepotinib monotherapy |
| Contraindicated monotherapy | crizotinib (active but inferior; reserve when selective MET-TKI unavailable) |
| Evidence summary | MET exon 14 skipping in advanced NSCLC (~3-4% of adenocarcinoma): capmatinib (GEOMETRY mono-1, Wolf 2020 — ORR 68% 1L / 41% prior-tx) and tepotinib (VISION, Paik 2020 — ORR 46% liquid + tissue) are selective MET-TKIs with FDA approval. Crizotinib has activity but is inferior; selective inhibitors preferred. |
Notes
ESCAT IA. OncoKB рівень 1. Виявлення: переважно RNA-NGS (ДНК-панелі можуть пропускати сплайс-варіанти у глибоких інтронних регіонах). Прогалина джерел: SRC-GEOMETRY-MONO-1 / SRC-VISION-PAIK-2020 ще не інгестовано.
Used By
No reverse references found in the YAML corpus.